Walking Fish Therapeutics, a South San Francisco, CA-based B cell engineering company, closed a $50M Series A financing.
The round was led led by Emerson Collective, Illumina Ventures and Quan Capital.
Co-founded by CEO Dr. Lewis “Rusty” Williams and Dr. Mark Selby, co-inventor of the immuno-oncology drug OPDIVO and multiple others, Walking Fish Therapeutics develops B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.
The company is developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.
FinSMEs
13/09/2021